Novo Nordisk announced Thursday that China approved its weight-loss drug Wegovy for a new indication.
The approval targets metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease.
This marks the first time China has approved a GLP-1 receptor agonist for MASH treatment.
The development expands Wegovy’s clinical applications from weight management and cardiovascular health into liver care.
This new indication solidifies the drug's role in the comprehensive management of obesity and its related complications.